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ABSTRACT:    
Population pharmacokinetic (PK) modeling methods can be statistically classified as 
either parametric or nonparametric (NP). Each classification can be divided into maximum 
likelihood (ML) or Bayesian (B) approaches. In this paper we discuss the nonparametric case 
using both maximum likelihood and Bayesian approaches. We present two nonparametric 
methods for estimating the unknown joint population distribution of model parameter values 
in a pharmacokinetic/pharmacodynamic (PK/PD) dataset. The first method is the NP Adaptive 
Grid (NPAG). The second is the NP Bayesian (NPB) algorithm with a stick-breaking process to 
construct a Dirichlet prior. Our objective is to compare the performance of these two methods 
using a simulated PK/PD dataset. Our results showed excellent performance of NPAG and NPB 
in a realistically simulated PK study.  This simulation allowed us to have benchmarks in the form 
of the true population parameters to compare with the estimates produced by the two 
methods, while incorporating challenges like unbalanced sample times and sample numbers as 
well as the ability to include the covariate of patient weight.  We conclude that both NPML and 
NPB can be used in realistic PK/PD population analysis problems.  The advantages of one versus 
the other are discussed in the paper. NPAG and NPB are implemented in R and freely available 
for download within the Pmetrics package from www.lapk.org. 
KEYWORDS: Population pharmacokinetic modeling, non-parametric, maximum likelihood, 
Bayesian, Stick-breaking, Pmetrics, RJags 
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INTRODUCTION  
 
Population pharmacokinetic (PK) modeling involves estimating an unknown population 
distribution based on data from a collection of nonlinear models. One important application of 
this method is the analysis of clinical PK data.  A drug is given to a population of subjects.  In 
each subject, the drug’s behavior is stochastically described by an unknown subject-specific 
parameter vector  . This vector   varies significantly (often genetically) between subjects, 
which accounts for the variability of the drug response in the population. The mathematical 
problem is to determine the population parameter distribution F( )  based on the clinical data.   
The distribution F  determines the variability of the PK model over the population.  
From an estimate of this distribution, means and credibility intervals can be obtained for all 
moments of F and, more generally, for any functional of F , such as a target serum 
concentration after a given dosage regimen. 
The importance of this problem is underscored by the FDA:  “Knowledge of the 
relationship among concentration, response, and physiology is essential to the design of dosing 
strategies for rational therapeutics. Defining the optimum dosing strategy for a population, 
subgroup, or individual patient requires resolution of the variability issues.” [1] 
Population PK modeling approaches can be classified statistically as either parametric or 
nonparametric. Each can be divided into maximum likelihood or Bayesian methods. While we 
focus on the nonparametric approaches in this paper, for completeness we discuss all four 
approaches very briefly below. 
 
The parametric maximum likelihood approach is the oldest and most traditional. One 
assumes that the parameters come from a known, specified probability distribution (the 
population distribution) with certain unknown population parameters (e.g. normal distribution 
with unknown mean vector  and unknown covariance matrix  ). The problem then is to 
estimate these unknown population parameters from a collection of individual subject data 
(the population data). The first and most widely used software for this approach has been the 
NONMEM program developed by Sheiner and Beal  [2], [3]. There are other parametric 
maximum likelihood programs currently available, such as Monolix  [4] and ADAPT  [5].  The 
ADAPT software also allows for parametric mixtures of normal distributions, see  [6] and  [7]. 
Asymptotic confidence intervals can be obtained about these population parameters. Here 
“asymptotic” means as the number of subjects in the population becomes large. 
 
The nonparametric maximum likelihood (NPML) approach was initially developed by 
Lindsay  [8] and Mallet  [9]. In contrast to parametric approaches, NPML makes no assumptions 

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about the shapes of the underlying parameter distributions.  It directly estimates the entire 
joint distribution. This permits discovery of unanticipated, often genetically determined, non-
normal and multimodal subpopulations, such as fast and slow metabolizers. The NPML 
approach is statistically consistent  [10]. This means that as the number of subjects gets large, 
the estimate of F given the data converges to the true F . Consequently so are its continuous 
functionals such as means and covariances.  The main drawback of the NPML approach is that it 
is not easy to determine even asymptotic confidence intervals about parameter estimates. For 
example, bootstrap methods have been used  [11], but are extremely computationally 
intensive. 
 
The Bayesian approaches are much newer. In the parametric Bayesian approach, one 
assumes that the population parameters (e.g. (, )  in the normal case)) are themselves 
random variables with known prior distributions. The problem then is to estimate the 
conditional distribution of the population parameters given the population data and the prior 
distributions. The most widely used approach is based on Monte Carlo Markov Chain (MCMC) 
methods.    
 
Population PK analysis can be performed using the software packages WINBUGS  [12], 
and JAGS  [13].  Because this method is Bayesian, rigorous credibility intervals can be obtained 
for population parameters independent of the sample size. Of course, questions remain about 
convergence of the MCMC sampler and sensitivity to the prior assumptions. 
 
The nonparametric Bayesian approach is much more flexible. One can assume that the 
population distribution F  is totally unknown and random with a Dirichlet process prior. This 
approach has only been applied to a few PK problems [14] [15], [16], [17]. A general purpose 
software package for population PK modeling has not been developed. This is one of the goals 
of the present paper. 
 
 THE NONPARAMETRIC APPROACHES 
 
We have developed two general nonparametric (NP) algorithms for estimating the unknown 
population distribution of model parameter values in a pharmacokinetic/pharmacodynamic 
(PK/PD) dataset [18], [19], [20].  The first method is the NP Adaptive Grid (NPAG) algorithm, 
which we have used in our USC Laboratory of Applied Pharmacokinetics for many years  [19]. 
This method calculates the maximum likelihood estimate of the population distribution with 
respect to all distributions.   Compared with most parametric population modeling methods, 
NPAG calculates exact, rather than approximate likelihoods, and it easily discovers unexpected 
sub-groups and outliers  [21], [22].  
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Since NPAG is an NPML method, it cannot easily calculate confidence intervals around 
parameter estimates. This motivated us to develop the second NP method described here. We 
used an NP Bayesian (NPB) algorithm with a stick-breaking process  [23], to construct a Dirichlet 
process prior. More details are given below. The NPB algorithm provides a Bayesian estimate of 
this totally unknown population distribution, including rigorous (not asymptotic) credibility 
intervals around all parameter estimates for any sample size.  
 
Both NPAG and NPB estimate the unknown population distribution as a discrete 
distribution.  These discrete representations are perfectly suited for multiple-model adaptive 
control in which required integrals over the population distribution become finite sums  [24].  
By combining discrete distributions that are free of a priori assumptions on shape with 
credibility intervals, NPB combines the best of parametric and nonparametric methods.  
 
The outline of the paper is as follows. First, we describe the mathematical and statistical 
details of the population PK/PD modeling problem. Then we describe the mathematical and 
statistical details of the NPAG and NPB algorithms. Next we give the results for our simulated 
PK/PD study data. The paper closes with conclusions and work for the future. 
 
THE POPULATION PK/PD MODEL 
Consider a sequence of experiments where each one consists of a dosage regimen and a set of 
measurements at several time points on one of N individual subjects. The measurement model 
for the ith subject is:  
(1)               
where the vectors   are the observed measurements, e.g. serum concentrations, PD effects, 
etc. The components of the vector  represent the unknown model and noise parameters 
defined on a space ;  represents the noise-free output depending on the dosage 
regimen and the measurement schedule. The noise vectors  are assumed to be independent, 
normal random variables with zero mean and covariance  
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The next two sections describe the mathematical and statistical details of the NPAG and NPB 
algorithms.  
NPAG ALGORITHM (NONPARAMETRIC ADAPTIVE GRID) 
 
NPAG is an adaptive grid algorithm for finding the nonparametric maximum likelihood estimate 
of the population distribution.  It was developed over a number of years at the Laboratory of 
Applied Pharmacokinetics, USC, by Alan Schumitzky  [25], Robert Leary  [26], and James Burke 
from the University of Washington, see also  [27].   
 
NPAG is based on a primal-dual interior point method.  In this paper we present a brief 
outline of this approach. Consider Eq. (1). The log likelihood is given by  
. 
The Maximum Likelihood distribution
MLF  maximizes  over the space of all 
distributions  defined on .  Using Caratheodory’s theorem and the results of Lindsay  [8] and 
Mallet  [9], it follows that 
MLF  can be found in the class of discrete distributions with at most N 
support points.   In this case we write 
 
(2)  
,
 
where  are the support points of ;   (       ) are the corresponding 
weights (probabilities) which sum to unity; and   is the Dirac measure with mass 1. 
 
Consequently, to maximize , it is sufficient to maximize 
 
with respect to the vectors and . If the support points  are known, then 
maximization of  with respect to the weights  in Eq. (3) is a convex 
optimization problem and can be solved very efficiently.   
 
The approach used in NPAG can be briefly described as follows: First solve the optimization 
problem for the weights related to Eq. (3) over a large but fixed grid of support points.  
Usually is taken to be a large number of so-called Faure points which optimally cover   
[28].  Then reduce the grid by deleting points with very low probability to get a new grid .  
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Then expand the grid by adjoining to each point in the vertices of a hypercube with 
as its center.  This adds points to  resulting in an expanded grid .  This cycle is 
repeated with replacing .  The process is continued until convergence is achieved.  
 
Optimization over fixed support points. 
The main part of the calculation comes in the optimization of the weights over a fixed grid of 
support points.  Start with a set of support points .  Let . Assume that the row 
sums of the  matrix are strictly positive (note that ). For 
any -dimensional vector  we can define the function: 
 
 
Maximizing Eq. (3) with respect to the weights  is equivalent to the solving the following 
two problems: 
 
(P)  Primal Problem:    Minimize  subject to  where  is the -
dimension column vector of with components all equal to one,  
 
Now , where  and .  The Fenchel convex 
dual is then given by the Dual problem: 
 
(D)  Dual Problem:   Minimize    subject to    
 
Duality Theorem and Karush-Kuhn-Tucker Conditions  
Solutions to (P) and (D) always exist, with the solution to (D) unique.  Also  solves (P) and  
solves (D) if and only if the Karush-Kuhn-Tucker  [29] [30]  conditions are satisfied: 
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where s is a non-negative N-dimensional vector (slack variables) and Q=diag(q), W=diag(w), 
Z=diag(z), S=diag(s). The primal-dual interior point method finds a solution to the above non-
linear system of equations  [27].  The Jacobian of the system is singular at the solution, so the 
strategy is to approach the solution along the central path   In this case, 
the equation is replaced by  and the (KKT) conditions become: 
  
The equations are solved by Newton’s method for a sequence of  values tending to 
zero. The limit solution then solves both the primal and dual problems.  The whole process 
converges quadratically and is very fast. 
Grid Adaptation: Reduction and Expansion 
As described earlier, the reduction of a current grid is accomplished by deleting support points 
with very low probability. The value of the likelihood function before and after grid reduction is 
essentially the same. The expansion of a current grid adds  points to the grid.  The 
optimization process over this new expanded grid can only increase the value of the likelihood 
function.  When this increase is essentially zero, the whole process has converged. Exact details 
of solving the equations and of grid adaptation will be published separately.  
NPB (NONPARAMETRIC BAYESIAN) 
There are two common ways to construct a Bayesian prior using a Dirichlet process: “marginal” 
and “full conditional” methods.  In the framework of our Nonparametric Bayesian algorithms 
we implemented both approaches as described below. We now consider Eq. (1) from a 
Bayesian point of view. In this case the distribution  is considered to be a random variable. 
The simplest prior distribution for  is the so-called Dirichlet process, see  [14] [17] for details.  
In this case we write  where the distribution  will be our prior estimate of ,  
and where the number  will be the strength of that guess. As before, we assume .  
Now the population analysis problem is to estimate the full conditional distribution of F given 
the data . Most methods to solve this problem employ a marginal approach.  However,   
can be “integrated out” leaving a much simpler problem for the  .  The resulting model for 
the    is given by the Polya Urn representation:    
 (w(),q()) as   0.
 WSe0   WSee
 
(KKT)    T q  s Ke  0
                z w  0   
               QZe e  0
               WSe   0  
 (KKT) 
 2
dim
 (KKT) 
 F
 F
 
F ~ D(G
0
)
0G F

 

i
~ F
 Y
N
F
i
i
Tatarinova et al, Journal of Pharmacokinetics and Pharmacodynamics, 2013, vol. 40 no 1 
DOI 10.1007/s10928-013-9302-8 
 
8 
 
 
The marginal approach leads to a Gibbs sampler algorithm for estimating , i.e., the 
expected value of given the data, but not its distribution function  [31]. This approach is 
commonly used. However, it does not solve the classical population analysis problem as stated 
above, for example,  to estimate the full conditional distribution of . To solve this problem we 
employ the Full Conditional Method.  In this we estimate the full conditional distribution of 
given the data , not just the expected value of . 
 The Full Conditional Method begins with a definition of the Dirichlet Process called the 
Stick-Breaking representation, see Sethuramam  [32] and Ishwaran and James  [23]. Consider 
the random distribution: 
(5)   
 where the random vectors  are independent and identically distributed (iid) from the 
known distribution  and the weights  are defined from the so-called stick-breaking 
process as follows:  
       (   )          
         (    )(    ) (      )  , for        , 
         ( -  )( -  ) ( -  - )   
where   is the Beta distribution with parameters . The name “Stick Breaking” 
comes from the fact that the  are random cuts on a stick of length 1 and the  are the 
lengths of the pieces broken off. This gives an informal proof that the sum to 1. It is shown 
in Sethuraman  [32] that the random distribution  if and only if can be written in 
the form of Eq. (5). 
Below we show how to use the Stick Breaking representation to estimate , not just 
. The estimate of  leads to an estimate of all moments and their 
corresponding credibility intervals.  More generally, the full conditional method can be used to 
estimate any functional of F, such as a target serum concentration profile to be achieved by a 
given dosage regimen, with its corresponding credibility interval.    
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 Ishwaran and James  [23] consider replacing the infinite sum in Eq. (5) by a truncated 
version:  
(6)        
,
 
where it is now required that so the series of weights sums to one.  They show that the 
truncated version is virtually indistinguishable from  for sufficiently large .  The only 
problem now is the size of . Ishwaran and James  [23] have suggested that  is 
sufficient.  In this paper we show that this number can be dramatically reduced. 
Note that Eq. (6) has exactly the same form as the Eq. (2) for .  The difference is that in Eq. 
(2), the weights  and support points  are deterministic, while in Eq. (6) the same 
quantities are random. In other words, is a deterministic distribution while is a random 
distribution. 
Full Conditional Approach.  Let us assume now that we have a sufficient number of 
components in Eq. (6) to approximate the infinite sum in Eq. (5) accurately.  Using Eqs. (3,5,6) 
we have the new model given by 
(7)          
where the random vectors are iid from the distribution  and the weights are defined by Eq. 
(5b) with .   
 Eq. (7) defines a mixture model with an unknown but finite number of components.  
Much is known about this subject [33], [34], [35].  For a fixed number of components , the 
posterior distribution of the weights  and the support points can be determined by 
the Blocked Gibbs Sampling [23].  Consequently, for a fixed , the posterior estimates of the 
support points  and the weights are straightforward to calculate.  As opposed to the 
Gibbs Sampler for the Marginal Method, the Gibbs Sampler for the NPB approach directly 
involves the distribution . 
Sampling the posterior of ,  and moments of .  
Let be samples of from the Gibbs Sampler after the 
sampler has “converged”.  Then we have:  
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Samples from the moments of :  Let  be the jth moment of .  
Then samples of  are given by:   . 
In particular, samples from the first moment or mean are given by 
. 
A histogram of the values of gives the estimated distribution of , and the 
Bayesian credibility intervals are derived from it. 
Samples from the expected value . For this quantity we calculate: 
.
 
To assess the performance of our algorithm, we can compare our estimate of with 
the estimate from the marginalization method.   
Choice of K.  We have implemented the Gibbs sampler from Ishwaran and James  [23], Sec. 5.2, 
using the software package JAGS  [13]. An important feature of this algorithm is that it keeps 
track of the number K* of distinct components in the K component mixture.    If K is chosen too 
small, the algorithm will alert the user by indicating that K*= K.  See  [36],  [37] for applications 
to pharmacokinetics using truncated stick-breaking methods. 
A more sophisticated way of choosing K is based on new results for Retrospective Sampling  
[31] and Slice Sampling  [38],  [39]. In these methods the infinite sum in the stick-breaking 
representation of Eq. (5) is retained but only as many terms in the sum are used as are needed 
in the calculation. 
COMPARISION OF NPAG AND NPB METHODS 
Both NPAG and NPB estimate the entire probability distribution  F  of PK/PD parameters in a 
population modeling setting.  NPAG is a deterministic method using the convexity of the 
resulting nonparametric maximum likelihood problem.  The optimization algorithm in NPAG is 
based on “state of the art” primal-dual interior-point theory.  It has been used in our laboratory 
for many years and can handle PK/PD problems defined by 20-30 differential and algebraic 
equations containing 20-30 unknown parameters. The algorithm is very stable and fast. It 
always determines an optimal solution to the problem.  The only drawback with NPAG is it does 
not directly determine confidence intervals of the parameters of interest.  (When the number 
of subjects in the population is large, then the asymptotic confidence intervals can be obtained 
with additional computing by bootstrap methods.) 
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NPB is a stochastic Monte Carlo Markov Chain (MCMC) method. The unknown probability 
distribution  F  is considered to be a random variable with a Dirichlet process prior.  The 
Dirichlet process is implemented with the Sethuraman's stick-breaking representation.   The 
algorithm used to estimate F   is a Metropolis-within-Gibbs sampling (GS) scheme.  For the 
example in this paper, the program JAGS is used to implement this scheme.  This 
implementation of GS is composed of three parts: First a number of samples of GS are burned 
to remove dependence on the initial conditions; then GS is run for a large number of iterations 
until “convergence” is achieved.  Then after convergence, GS is run some more to get the 
samples used for the actual estimation and plotting of results.  The number of samples required 
for convergence is a delicate issue.   There are many candidates to test convergence of MCMC 
algorithms. No one method is perfect. We use the Gelman-Rubin method of parallel chains to 
determine convergence.  Finally, being a Bayesian method, NPB can provide rigorous credibility 
intervals for any function of interest of the PK/PD parameters.  These credibility intervals are 
accurate in both large and small population sample sizes. 
In conclusion, for a given set of initial conditions, NPAG will always give the same results, 
whereas NPB may possibly give different results depending on the sampling scheme.  On the 
other hand, no confidence intervals are available with NPAG (without asymptotic bootstrap), 
while rigorous Bayesian credibility intervals are defined for NPB no matter what the sample 
size. Consequently, it is extremely useful to be able to run both NPAG and NPB side by side and 
compare the results (as shown in this paper). 
Finally, both NPAG and NPB estimate F   with a finite discrete probability distribution (as 
described in the paper).  This result is vital for our resulting maximally precise “multiple model” 
dosage optimization and experimental design programs. 
EXAMPLE: A POPULATION PK STUDY 
We took dosing, sample times, and body weights from N=35 infants enrolled in an IV 
zidovudine PK study as a template to simulate new observations after a short intravenous (IV) 
infusion of a hypothetical drug into a one compartment model with simulated PK parameter 
values.  This provided a realistic simulated dataset with unbalanced doses, number of samples 
numbers and sample times in the population, but with known PK parameter values for each 
subject.  We used the Monte Carlo simulator function in our R package Pmetrics [21]. In short, 
Pmetrics is our freely available R package for non-parametric and parametric population 
modeling and simulation. It can model multiple inputs and outputs simultaneously, with 
complex dosing regimens, inclusion of covariates, lag times, and non-zero initial conditions all 
available to the user.  Specification of a model, based on algebraic equations or differential 
equations and incorporating any function of parameters and covariates, is done with a very 
simple text file.  Detailed examples and model files can be found at http://www.lapk.org. 
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Simulation model. For the PK parameter values, we set the elimination rate constant 
 (Kel)  
as a mixture of two normal distributions with arbitrary means of 0.5 and 1.0 1/h and weights of 
0.3 and 0.7. The population average was equal to 0.85 1/h and located in the ''valley" between 
the two modes. These parameter values produced realistic time-concentration profiles.  The 
coefficients of variation (CV) for each distribution were set at 25%. We set the volume of 
distribution to be a single normal distribution, with a mean of 2.0 L/kg and standard deviation 
of 0.5 L/kg. The measurement noise, as a normal distribution with mean 0 and standard 
deviation σe=0.01, was added to each simulated observation. 
Hence, we consider a one compartment model with T=5 or 6 serum measurements (specific for 
each patient) for a population of N=35 subjects.  In this case ; where  is  bimodal 
and is unimodal.  Therefore the model that was used to simulate the data is described by the 
following equations: 
-( )-
 (1-  ) ,   1,..., ;   1,...,iij ij i
i i i
ij i ii i
t ddR
Y e e e i N j n
WtV



   
  
~ (0,0.01)ije N  
)25.0,0.1(7.0)125.0,5.0(3.0~ NNi   
)5.0,0.2(~ NVi  
where Ri is the subject-specific infusion rate with di infusion duration for zidovudine; Wti is the 
body weight in kg for each subject; tij is the time of the j
th sample from subject i; and eij  is the 
measurement noise of the jth measurement noise in subject i.  Values of Ri, Wti, di were the 
defined patient-specific parameters in the original population of infants. The symbol ~ means 
“distributed as”.  To avoid negative parameter values we also set:          and        . 
 
Estimation Model. The NPB model used to analyze the data came from the stick-
breaking representation, with K=17, see Eq. (6).  This number of stick breaks (support points) 
for the NPB prior was based on the number of clusters created by the NPB algorithm and was 
determined by a manual iterative approach. If more than 17 support points were used the 
resulting probabilities assigned to additional support points were negligible. The base measure 
),(0 VG   was given by: 
 
0 0 0 0
0 0 0 0
~ ( ,1/ ), ~ (0.8,0.5), ~ Gamma(1,1)
~ ( ,1/ ), ~ (2.0,0.5), ~ Gamma(1,1)V V
N N
V N V V N
     
 
 
where Gamma(a,b) is the gamma distribution with parameters a,b. These are the common 
distributions traditionally chosen for means and variances. The user of the program can also 
make other choices. 
  
),( V 
 V
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Using the NPAG algorithm  [19] from the Pmetrics software package  [21], we calculated the 
maximum likelihood distribution  
MLF , see Figure 2.  Implementing the stick-breaking 
algorithm using the Rjags package  [40], we calculated the estimated conditional distribution 
MLF , shown in Figure 2.  For the NPB algorithm, we used one Markov Chain for the Monte 
Carlo simulation, drawing every 10th posterior sample from iteration 10,000 to 10,500. 
 
As a further comparison, we also fitted the data with the NONMEM FOCE algorithm, with V and 
K modeled as univariate normal distributions with an additive measurement error eij.  
 
Results 
 
Simulated observations with realistic, unbalanced sampling times and sample numbers ranged 
from <0.01 to 1.64 mg/L, calculated up to 8 hours after dosing, with 5–6 samples per subject at 
times that varied throughout the population, and which corresponded to the times that real 
infants in the source population had been sampled. Figure 1 shows the simulated time-series. 
The whole NPAG optimization, including post-processing and report generation, took 18 
seconds on a MacBook Pro with 2.54 GHz Intel core 2 Duo processors and 4 GB of RAM. On the 
same computer, NPB took 2 minutes. 
Summaries of the simulated (True) values for KEL and VOL and of the weighted support points 
fitted by the NPB, NPAG and FOCE algorithms are shown in the Table 1. Figures 2-5 show the 
output of the NPB algorithm. In the Figures 2 and 3, the NPB estimates for Vol and Kel are 
plotted against the histogram of simulated values for volume of distribution. Figures 4 and 5 
show NPB error in true - fitted parameter values for comparison of NPB estimated vs. the 
simulated values for volume of distribution and elimination constant. Figures 6 and 7 show the 
NPAG estimates for Vol and Kel compared against the histogram of simulated values for volume 
of distribution.  
  
 
For 35 subjects NPB estimates values Vol and Kel for individual patients, but the estimated 
parameter distribution functions have too many peaks as compared to the "true" parameter 
distributions. When we increase the number of subjects to 70 or more (data not shown), the 
estimated parameter distribution functions has two modes for Kel and one mode for Vol, and 
parameter distributions approach the true population distributions. However, due to the 
nature of our simulation study (infant HIV patients enrolled in an IV zidovudine PK study) it is 
not realistic to expect large cohorts in a clinical setting.  
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DISCUSSION 
Bayesian methods are rapidly gaining recognition and popularity. A comprehensive overview of 
the general philosophy of Bayesian methods can be found in the book "The Bayesian Choice" 
[41]. Computational issues of MCMC methods are well described in "Monte Carlo Statistical 
Methods" [42]. Biostatistics applications are described in the chapter "Nonparametric Bayes 
Applications to Biostatistics" [43].  To the best of our knowledge, currently there are no 
textbooks that primarily discuss nonparametric pharmacokinetic modeling. However, our 
references [14], [15], [16], [17], [18] provide a good survey of this subject.   
 
We have described two novel methods, NPAG and NPB, to estimate the population distribution 
F of PK parameters, have shown their excellent performance in a realistically simulated PK 
study. We also compared their performance to NONMEM, the widely-used FOCE algorithm. In 
this simple model, FOCE, a parametric method, was able to find the same the mean parameter 
values and standard deviations, but could not find the true non-normal distribution for K 
without resorting to post-hoc estimates.  In contrast, both NPAG and NPB are able to directly 
estimate the true distribution.  In future work beyond our proof-of-principle work on NPB here, 
we will show that more "challenging" data with greater noise and non-normal parameter value 
distributions are even better fitted by optimized non-parametric methods, i.e. NPAG and NPB.  
In this paper, our simulation allowed us to have benchmarks in the form of the true population 
parameter values to compare with the estimated values, while incorporating challenges like 
unbalanced sample times and sample numbers as well as the ability to include the covariate of 
patient weight. 
 
The statistical problem of estimating  has a direct utility in the form of individualized therapy 
of future patients because the estimate of can be used quickly and accurately to isolate a 
new patient's characteristics (i.e., parameters) and use this knowledge to tailor patient-specific 
efficacious treatment.  The NPB method is very flexible and has been used in many areas of 
applied statistics and bioinformatics outside PK, discussed, for example,  in [43]. 
 
NPAG and NPB represent two ends of the spectrum spanning frequentist (NPAG) to Bayesian 
(NPB) methodologies; they estimate the entire distribution , not just parameter values. The 
two methods are the state-of-the-art in nonparametric population modeling, and they 
accurately estimate the parameter distributions without resorting to any a priori assumptions 
about the underlying form of these distributions. While NPAG is significantly faster at present, 
the main advantage of the NPB method is that it naturally allows for robust credibility intervals 
for all parameter estimates.   
 F
 F
 F
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The simulation study presented above is performed in the setting of a real zidovudine trial 
which allows us to have benchmarks in the form of the true population parameters to compare 
with the estimates produced by the two methods, while incorporating realistic challenges like 
unbalanced sample times and sample numbers as well as the ability to include the covariate of 
patient weight. Figures 2-7 and Table 1 show that both methods focus on the marginal 
distributions of Kel (elimination rate constant) and Vol (volume of distribution) in our example 
and produce accurate estimates of their moments.  We have previously shown that NPAG, as 
implemented in our Pmetrics R package, can directly and accurately detect true non-normal 
parameter distributions and outliers in an idealized simulated population [21]. In addition to 
confirming this property of NPAG with a more realistic study design here, we extend this 
property to our NPB algorithm. 
 
Future refinements of the NPB algorithm include exploring convergence criteria, 
implementation of the Retrospective and Slice sampling methods to determine the correct 
number of stick breaks (i.e. support points, as opposed to the empiric approach described 
here), and generalization to even more complex PK models, including arbitrary models defined 
by ordinary differential equations. The software used to implement NPAG and NPB can be 
obtained from http://lapk.org/software.php. 
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Figure 2: NPB distribution and simulated values for volume of distribution (VOL).  Marginal 
distributions for simulated (true) parameter values are shown in black circles and seven filled 
histograms. The posterior distribution is represented in two ways 1) dark grey bars with binning 
(nbins=50) and 2) a smoothed sum of normal distributions about the means of the distributions for 
each of the 17 support points (solid black line). True population distribution is shown as a dashed 
line. 
 
 
  
Tatarinova et al, Journal of Pharmacokinetics and Pharmacodynamics, 2013, vol. 40 no 1 
DOI 10.1007/s10928-013-9302-8 
 
23 
 
Figure 3: NPB distribution and simulated values for elimination rate constant (KEL). Marginal 
distributions for simulated (true) parameter values are shown in black circles and filled histograms. 
The posterior distribution is represented in two ways 1) dark grey bars with binning (nbins=50) and 
2) a smoothed sum of normal distributions about the means of the distributions for each of the 17 
support points (solid black line). True population distribution is shown as a dashed line. 
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Figure 4: NPB error in true - fitted parameter values (VOL). Linear regression of simulated volume of 
distribution vs. predicted volume of distribution for each of the 35 simulated subjects using NPB 
algorithm.   
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Figure 5: NPB error in true - fitted parameter values (KEL). Linear regression of simulated elimination 
constant vs. predicted elimination constant for each of the 35 simulated subjects using NPB 
algorithm.   
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Figure 6: NPAG distribution and simulated values for volume of distribution (VOL). Distribution of 
simulated (true) parameter values are shown in black circles. The posterior distribution is 
represented by dark grey bars. True population distribution is shown as a dashed line. 
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Figure 7: NPAG distribution and simulated values for elimination rate constant (KEL). Distribution of 
simulated (true) parameter values are shown in black circles. The posterior distribution is 
represented by dark grey bars. True population distribution is shown as a dashed line. 
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Figure 8: NPAG error in true - fitted parameter values (VOL). Linear regression of simulated volume 
of distribution vs. predicted volume of distribution for each of the 35 simulated subjects using NPAG 
algorithm.   
 
  
Tatarinova et al, Journal of Pharmacokinetics and Pharmacodynamics, 2013, vol. 40 no 1 
DOI 10.1007/s10928-013-9302-8 
 
29 
 
Figure 9: NPAG error in true - fitted parameter values (KEL). Linear regression of simulated 
elimination constant vs. predicted elimination constant for each of the 35 simulated subjects using 
NPAG algorithm.   
 
 
